Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Common Equity (2021 - 2025)

Historic Common Equity for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $161.8 million.

  • Prime Medicine's Common Equity fell 1460.81% to $161.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.8 million, marking a year-over-year decrease of 1460.81%. This contributed to the annual value of $153.1 million for FY2024, which is 1508.82% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Common Equity is $161.8 million, which was down 1460.81% from $60.9 million recorded in Q2 2025.
  • Prime Medicine's 5-year Common Equity high stood at $316.3 million for Q4 2022, and its period low was -$223.1 million during Q3 2022.
  • In the last 5 years, Prime Medicine's Common Equity had a median value of $153.1 million in 2024 and averaged $84.7 million.
  • Within the past 5 years, the most significant YoY rise in Prime Medicine's Common Equity was 30242.58% (2022), while the steepest drop was 13628.55% (2022).
  • Over the past 5 years, Prime Medicine's Common Equity (Quarter) stood at -$156.2 million in 2021, then soared by 302.43% to $316.3 million in 2022, then crashed by 57.92% to $133.1 million in 2023, then rose by 15.09% to $153.1 million in 2024, then rose by 5.66% to $161.8 million in 2025.
  • Its last three reported values are $161.8 million in Q3 2025, $60.9 million for Q2 2025, and $106.9 million during Q1 2025.